Jeito Capital strengthens its Executive Committee with the appointment of Sarah Leroy who is taking the newly created position of Secretary General responsible for managing Legal and Financial Affairs, Compliance, HR and Sustainability

Paris, France, March 14th 2024 – Jeito Capital (“Jeito”), a global leading independent private equity fund dedicated to biopharma, is pleased to announce the appointment of Sarah Leroy who is taking the newly created position of Secretary General responsible for managing Legal and Financial Affairs, Compliance, HR and Sustainability. Sarah becomes a member of the Executive Committee of Jeito Capital.

This new position reflects Jeito’s growth dynamic, with a two-fold objective: contribute to the development of Jeito Capital and its portfolio companies. Sarah will bring over 25 years of experience in her respective fields to the team, having worked for major international groups and a leading alternative asset manager.

Sarah’s extensive knowledge and experience in corporate governance, as well as the structuring and management of complex financial transactions and operations within leading global corporations, will contribute to Jeito Capital’s operational and international development.

Dr. Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital, said: “I am very happy to welcome Sarah, whose appointment marks a new stage in our growth dynamic. The creation of this new position reflects our desire to combine the efforts of our teams with those of our cross-functional teams to amplify value creation at Jeito Capital and its portfolio companies.  Our portfolio companies from France and the United States all serve a common and ambitious objective: to accelerate therapeutic innovation for the benefit of patients.”

Sarah Leroy, Secretary General and Member of the Executive Committee, added: “I’m delighted to be joining the Jeito team and contributing to its expansion alongside its team of experts dedicated to collectively make a difference for patients. I’d like to thank Rafaèle for her trust and I’m looking forward to developing innovation with a strong human and social impact.”

Biography of Sarah Leroy:

With a French-British background, Sarah is a member of the Paris Bar and holds a double masters degree in private and public law (Faculté de droit d’Orléans) and an LLM (Master of Laws – University of Northumbria, UK). She began her career in the M&A teams of international law firms (August Debouzy (2000-2003) and Jones Day (1996-1999)), where she led numerous transactions (fund-raising, mergers, disposals, formation of joint ventures, etc.), particularly in the real estate and industrial sectors.

In 2003, she joined AXA IM Alts (formerly AXA IM Real assets), the European leader in alternative asset management, as Head of Legal – Corporate Finance, before becoming Global Head of Legal and member of its Executive Committee in 2011. She was involved in the deployment of the Group’s investment strategies and its expansion in the United States and Asia-Pacific, and lead the international team responsible for structuring and launching funds and assisting with the various financial transactions.

With 15 years’ experience behind her, Sarah Leroy joined Tereos, the cooperative group and the world’s 2nd largest global producer of sugar, in 2018 as the group’s Legal, Tax, Compliance and Insurance Director, a member of the Executive Committee and a board member of several subsidiaries. In 2023, in addition to her duties, the Group entrusted her with the Human Resources Department, and she was also appointed Secretary to the Nomination and Remuneration Committee.

In 2018, she became a Board member of the AFJE (Association Française des Juristes d’Entreprise) before being appointed Vice-President in 2019.

About Jeito Capital

Jeito Capital is a global leading Private Equity company with a patient-benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States.

For more information, please visit or follow us on Twitter or LinkedIn.

For further information please contact:

Jeito Capital
Rafaèle Tordjman
Jessica Fadel, EA
Tel: +33 6 33 44 25 47

H/Advisors Maitland
David Stürken
Tél. : +44 (0) 799 059 5913